Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Annexon stock | $28.98

Own Annexon stock in just a few minutes.

Fact checked

Annexon, Inc is a biotechnology business based in the US. Annexon shares (ANNX) are listed on the NASDAQ and all prices are listed in US Dollars. Annexon employs 38 staff and has a market cap (total outstanding shares value) of USD$1.1 billion.

How to buy shares in Annexon

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Annexon. Find the stock by name or ticker symbol: ANNX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Annexon reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$28.98, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Annexon, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Annexon. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Annexon share price

Use our graph to track the performance of ANNX stocks over time.

Annexon shares at a glance

Information last updated 2020-12-29.
Latest market closeUSD$28.98
52-week rangeUSD$15.33 - USD$31.94
50-day moving average USD$25.2962
200-day moving average USD$24.7023
Wall St. target priceUSD$34.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.2242

Buy Annexon shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Annexon stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Annexon price performance over time

Historical closes compared with the close of $28.98 from 2020-12-18

1 week (2021-01-08) 29.90%
1 month (2020-12-16) 12.15%
3 months (2020-10-16) -4.42%
6 months (2020-07-12) N/A
1 year (2020-01-12) N/A
2 years (2019-01-12) N/A
3 years (2018-01-12) N/A
5 years (2016-01-12) N/A

Annexon financials

Gross profit TTM USD$0
Return on assets TTM -14.22%
Return on equity TTM -23.55%
Profit margin 0%
Book value N/A
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Annexon shares

There are currently 572,177 Annexon shares held short by investors – that's known as Annexon's "short interest". This figure is 2.5% down from 586,788 last month.

There are a few different ways that this level of interest in shorting Annexon shares can be evaluated.

Annexon's "short interest ratio" (SIR)

Annexon's "short interest ratio" (SIR) is the quantity of Annexon shares currently shorted divided by the average quantity of Annexon shares traded daily (recently around 73544.601542416). Annexon's SIR currently stands at 7.78. In other words for every 100,000 Annexon shares traded daily on the market, roughly 7780 shares are currently held short.

However Annexon's short interest can also be evaluated against the total number of Annexon shares, or, against the total number of tradable Annexon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Annexon's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Annexon shares in existence, roughly 20 shares are currently held short) or 0.0168% of the tradable shares (for every 100,000 tradable Annexon shares, roughly 17 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Annexon.

Find out more about how you can short Annexon stock.

Annexon share dividends

We're not expecting Annexon to pay a dividend over the next 12 months.

Annexon overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site